Renata has entered the Canadian pharmaceutical market with the launch of a birth control pill, aiming to expand its export portfolio and diversify its global presence.
The company introduced Desogestrel/Ethinyl Estradiol (0.15 mg/0.03 mg) tablets, a birth control pill that combines two hormones-desogestrel (a progestin) and ethinylestradiol (an estrogen)-to prevent pregnancy when taken properly.
The development was disclosed in a stock exchange filing on Wednesday.
The tablets, manufactured at Renata's Health Canada-approved potent product facility, will be marketed under the brand names Miley 21 and Miley 28 through a strategic partnership with Ambicare Pharmaceuticals Inc.
Ambicare, a generic drug company with a broad portfolio across multiple therapeutic areas, has a strong footprint in the Canadian market.
"Entering the strictly regulated Canadian market through this partnership marks a historic milestone for Renata," said Md Jubayer Alam, company secretary of Renata. He added that the company also markets the same product in Bangladesh under the brand name Desolon.
Building on its expertise in navigating tough regulatory regimes, Renata aims to expand its product portfolio in Canada as part of its broader export strategy. "As the company has started exporting to Canada, we hope exports will increase in the future," Mr Alam said.
Renata recently launched Fludrocortisone 0.1 mg tablets in the UK, supplied from its UK MHRA (Medicines and Healthcare products Regulatory Agency)-approved facility. Fludrocortisone is a synthetic corticosteroid used in the treatment of Addison's disease and salt-losing adrenogenital syndrome.
The company sees strong export opportunities in the UK and EU markets, while also expanding across North America and Australia. Last year, Renata entered the US and Australian markets, pushing its global footprint to more than 50 countries.
Exports rose 4 per cent year-on-year in FY24, while export revenue jumped 22.5 per cent in the nine months through March this year, according to company data.
"These global milestones have been possible due to Renata's commitment to compliance with stringent regulatory frameworks, robust state-of-the-art manufacturing facilities, and partnerships with global distributors, ensuring reliable supply chains and patient-centric delivery," the company said.
babulfexpress@gmail.com
© 2025 - All Rights with The Financial Express
